Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Lung Cancer
84%
Progression-free Survival
54%
Immune Checkpoint Inhibitors
44%
Lung Adenocarcinoma
43%
Monotherapy
40%
Small Cell Lung Cancer
38%
Immune Checkpoint Inhibitor Therapy
36%
Chemotherapy
30%
Adverse Effects
25%
Prognostic Factors
24%
Sirtuin 1 (SIRT1)
22%
Elderly Patients
22%
Tumor
22%
Clinical Course
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Programmed Death-ligand 1 Expression
18%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
17%
Performance Status
17%
Egfr
17%
Clinical Parameters
17%
Patient Characteristics
16%
Older Men
16%
Lactate Dehydrogenase
15%
Programmed Death-ligand 1 (PD-L1)
15%
Non-squamous
15%
Squamous Cell
15%
Young Patients
14%
Asthma
14%
Nivolumab
13%
Systemic Therapy
13%
Appetite Loss
13%
Ischemic Heart Disease
13%
Body Mass Index
12%
Postoperative Recurrence
12%
Pemetrexed
12%
EGFR Status
12%
Leptomeningeal Carcinomatosis
12%
Gefitinib
12%
Right Upper Lobe
12%
T790M mutation
12%
Comorbidity
12%
Overall Survival
12%
Confidence Interval
11%
Pembrolizumab
11%
C-ratio
11%
Chemotherapy-induced
11%
Mouse Model of Asthma
11%
Irinotecan
11%
Total Adiponectin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
61%
Chemotherapy
51%
Immune Checkpoint Inhibitor
45%
Progression Free Survival
45%
Epidermal Growth Factor Receptor
45%
Retrospective Study
42%
Small Cell Lung Cancer
41%
Monotherapy
39%
Lung Cancer
35%
Adverse Event
33%
Programmed Death 1 Ligand 1
25%
Neoplasm
24%
Overall Survival
23%
Lactate Dehydrogenase
18%
Recurrent Disease
16%
Asthma
15%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Disease
14%
Inflammation
13%
Disease Course
13%
Messenger RNA
12%
Squamous Cell Lung Carcinoma
11%
Creatinine
11%
Irinotecan
11%
Chronic Obstructive Lung Disease
11%
Cystatin C
11%
Carcinoma
11%
Mouse Model
11%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
11%
Carnitine
11%
Ovalbumin
11%
Wheezing
11%
Sirtuin 1
11%
Loss of Appetite
11%
Hydrocortisone
11%
Valaciclovir
11%
Pemetrexed
11%
Cisplatin
11%
Radiation Pneumonia
11%
Amrubicin
11%
Ischemic Heart Disease
11%
Neurotoxicity
11%
Pharmacokinetics
11%
Fibrosis
9%
Docetaxel
9%
Observational Study
9%
Minoxidil
8%
Lung Adenocarcinoma
8%
Pembrolizumab
6%
Autoimmune Hemolytic Anemia
5%
Medicine and Dentistry
Lung Cancer
82%
Non Small Cell Lung Cancer
53%
Immune Checkpoint Inhibitor
51%
Lung Adenocarcinoma
43%
Retrospective Study
30%
Progression Free Survival
24%
Chemotherapy
23%
Lung
21%
Disease Course
21%
Monotherapy
20%
Epidermal Growth Factor Receptor
18%
Adverse Event
17%
Small Cell Lung Cancer
17%
Recurrent Disease
16%
T-Helper Cell
14%
Nivolumab
13%
Systemic Therapy
13%
Loss of Appetite
13%
Lactate Dehydrogenase
12%
Patient Characteristics
12%
Gefitinib
12%
Meningeal Carcinomatosis
12%
Comorbidity
12%
Overall Survival
11%
Neoplasm
11%
Immunotherapy
11%
Local Therapy
11%
Mouth Squamous Cell Carcinoma
11%
Hamartoma
11%
Pneumocystis Pneumonia
11%
Lung Metastasis
11%
T Lymphocyte
11%
Oral Cancer
11%
Hydrocortisone
11%
Gastroenteritis
11%
Septic Arthritis
11%
Amrubicin
11%
Sirtuin1
11%
Evacuation
11%
Carcinoma
11%
Lung Aspergillosis
11%
Chronic Obstructive Pulmonary Disease
11%
Resuscitation
11%
Afatinib
11%
Physical Activity
11%
Peripheral Blood Mononuclear Cell
11%
Liver Toxicity
11%
Erlotinib
11%
Wheeze
11%
Body Mass Index
11%
